Jubilant Pharmova Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for JUBLPHARMA, BSE:530019 Jubilant Pharmova Ltd.

Search Inside the pdf :

Jubilant Pharmova Ltd.

05 Nov 2025

1086.00

-0.56%

Jubilant Pharmova

Buy: Jubilant Pharmova Ltd.

Recommendation Target

ICICI Direct

We continue to focus on Jubilant's flagship segments such as Radiopharmaceuticals, Allergy Immunotherapy, CDMO Sterile Injectables and Drug Discovery Services which together contribute ~53% of the sales and more than 90% of the EBITDA on the back of their high-margin profile. Their performances are also critical in order to achieve the management's aspirational target for FY30 - doubling of overall revenues (FY24 base),...

Jubilant Pharmova Ltd. has an average target of 1415.00 from 1 broker.

Jubilant Pharmova Ltd.

29 Oct 2022

1086.00

-0.56%

Jubilant Pharmova

Hold: Jubilant Pharmova Ltd.

Recommendation Target

ICICI Direct

Jubilant Pharmova Ltd. has an average target of 1415.00 from 1 broker.

Jubilant Pharmova Ltd.

25 Oct 2022

1086.00

-0.56%

Mixed bag; valuations provide comfort

Buy: Jubilant Pharmova Ltd.

Recommendation Target

ICICI Securities Limited

Jubilant Pharmova’s (Jubilant) Q2FY23 performance was a mixed bag with revenue declining 3.5% YoY to Rs16bn due to generics business and tapering of covid-related revenues but ahead of our estimated sales of Rs15bn.

Jubilant Pharmova Ltd. has an average target of 1415.00 from 1 broker.

Jubilant Pharmova Ltd.

03 Aug 2022

1086.00

-0.56%

Margin pressure continues

Accumulate: Jubilant Pharmova Ltd.

Target

ICICI Securities Limited

Jubilant Pharmova’s (Jubilant) Q1FY23 missed our estimates on the profitability front, while reported revenue was as expected. Revenues declined 11.2/5.0% YoY/QoQ to Rs14.5bn due to lower CDMO sales with covid-related deals tapering off. EBITDA margin declined 970bps/290bps YoY/QoQ to 13.3% (I-Sec: 15.5%) and adjusted PAT declined 70.7% YoY to Rs470mn.

Jubilant Pharmova Ltd. has an average target of 1415.00 from 1 broker.

Jubilant Pharmova Ltd.

03 Aug 2022

1086.00

-0.56%

Jubilant Pharmova

Sell: Jubilant Pharmova Ltd.

ICICI Direct

Jubilant Pharmova Ltd. has an average target of 1415.00 from 1 broker.

Jubilant Pharmova Ltd.

08 Feb 2022

1086.00

-0.56%

Jubilant Pharmova

Hold: Jubilant Pharmova Ltd.

Target

ICICI Securities Limited

Revenue break up (FY21)- Formulations - 24%, Radiopharma and allergy therapy 38% and CDMO & API 33% Q3FY22 Results: Generics and CDMO business were affected due to multiple headwinds leading to reduction in operating leverage....

Jubilant Pharmova Ltd. has an average target of 1415.00 from 1 broker.

Jubilant Pharmova Ltd.

05 Feb 2022

1086.00

-0.56%

Weak 3Q, muted outlook; downgrade to Neutral

Neutral: Jubilant Pharmova Ltd.

Recommendation Target

Motilal Oswal

Jubilant Pharmova (JP) delivered 3QFY22 earnings far below our expectations, led by a weak Generics / Contract Development and Manufacturing Organization (CDMO) business and a sharp reduction in operating leverage. While the Radiopharma business posted YoY growth in 3QFY22, the recent surge in COVID cases has impacted the business on a QoQ basis. We cut our FY22E/FY23E/FY24E EPS estimate by 40%/45%/35% to factor in a) the adverse impact in the Generics business due to an import alert at Roorkee, b) pricing pressure in the US market, c) lower COVID-driven business, d) the...

Jubilant Pharmova Ltd. has an average target of 1415.00 from 1 broker.

Jubilant Pharmova Ltd.

25 Oct 2021

1086.00

-0.56%

Jubilant Pharmova

Hold: Jubilant Pharmova Ltd.

Recommendation Target

ICICI Securities Limited

Formulations - 24% of FY21 revenues, Radiopharma and allergy therapy 38% and CDMO & API 33% of sales Q2FY22 Results: Below I-direct estimates, especially on the CDMO front....

Jubilant Pharmova Ltd. has an average target of 1415.00 from 1 broker.

Jubilant Pharmova Ltd.

24 Jul 2021

1086.00

-0.56%

Radiopharma on a gradual recovery path

Buy: Jubilant Pharmova Ltd.

Target

Motilal Oswal

JP delivered in line earnings, despite a better than expected revenue in 1QFY22. The COVID-related business led to a strong YoY revenue growth. However, reduced number of lung procedures in the Radiopharma segment, increased price erosion in the Sartans portfolio, and price erosion in the base portfolio in the Generics segment led to lower-than-expected profitability, offsetting benefits of higher revenue. We have reduced our FY22E/FY23E EPS estimate by 14% each to factor in: a) delay in potential products on account of the import alert at Roorkee, b)...